The University of Rochester received a $385,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award, issued on May 1, 2021 and concluding on April 30, 2023, will support the development of UR238, a small-molecule inhibitor of HE4 being investigated for treatment of ovarian cancer. Through this funding, the University of Rochester will conduct research towards transforming healthcare and investigating medical solutions for the battlefield by developing the first inhibitor of this potential ovarian cancer target located in Rochester, New York.
Generated 1/6/24, 12:54 PM